Latest Period
Q2 2026
Security Snapshot
Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) Institutional Ownership
CUSIP: 28658R106
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2026
Institutions Reporting
108
Shares (Excl. Options)
56,329,219
Price
$13.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- CLYM on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 56,329,219
- Total 13F value
- $734,345,136
- Portfolio coverage rank
- 0%
- Share change
- +24,063,740
- Value change
- +$352,395,622
- Number of holders
- 108
- Shares outstanding
- 57,061,882
- SEC-reported price per share
- $12.58
- Insider filing price
- $12.58
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CLYM - Climb Bio, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 28658R106.
- 108 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 78 to 108 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $221,168,507 to $734,345,136.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 108 institutions filings for Q2 2026.
Security key
28658R106
Latest holder period
Q2 2026
13F holders
108
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
CLYM full holder history
Climb Bio, Inc. SEC filings
Climb Bio, Inc. company facts
Climb Bio, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28658R106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
CLYM
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 33% | 0% | $258,995,932 | +$6,882,125 | 23,249,186 | +2.7% | RA Capital Management, L.P. | 02 Jul 2026 |
| FMR LLC | 12% | $75,644,655 | 6,790,364 | FMR LLC | 30 Jun 2026 | |||
| Pontifax Management 4 G.P. (2015) Ltd. | 7.7% | $12,911,822 | 5,206,380 | Pontifax VI G.P. L.P. | 27 Jun 2024 |
As of 30 Jun 2026, 108 institutional investors reported holding 56,329,219 shares of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM). This represents 99% of the company’s total 57,061,882 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
88%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20% | 11,300,939 | 0% | 1.3% | $147,364,245 |
| FMR LLC | 12% | 6,790,364 | +106049% | 0% | $88,546,347 |
| UBS Group AG | 6% | 3,404,866 | +3862% | 0.01% | $44,399,453 |
| BRAIDWELL LP | 4.9% | 2,797,375 | +83% | 1.3% | $36,477,770 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.4% | 2,506,000 | 0.05% | $32,678,240 | |
| BlackRock, Inc. | 4.1% | 2,354,872 | +486% | 0% | $30,707,531 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.7% | 2,127,281 | +11% | 0% | $27,741,000 |
| Cormorant Asset Management, LP | 3.7% | 2,106,000 | 1.4% | $27,462,240 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 3.4% | 1,939,019 | 0.24% | $25,284,808 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3% | 1,698,654 | +44% | 0% | $22,150,448 |
| Woodline Partners LP | 2.8% | 1,582,291 | 0.06% | $20,633,075 | |
| CITADEL ADVISORS LLC | 2.3% | 1,297,972 | +276% | 0.01% | $16,925,555 |
| Redmile Group, LLC | 2.1% | 1,226,330 | 1.1% | $15,991,343 | |
| GREAT POINT PARTNERS LLC | 1.8% | 1,000,000 | -25% | 3.1% | $13,040,000 |
| Affinity Asset Advisors, LLC | 1.7% | 972,000 | +39% | 0.62% | $12,674,880 |
| MILLENNIUM MANAGEMENT LLC | 1.6% | 908,198 | -29% | 0.01% | $11,842,902 |
| ADAR1 Capital Management, LLC | 1.4% | 822,649 | +38% | 0.51% | $10,727,343 |
| Driehaus Capital Management LLC | 1.4% | 790,000 | +31% | 0.06% | $10,301,600 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 782,199 | +150% | 0% | $10,202,039 |
| STEMPOINT CAPITAL LP | 1.3% | 742,745 | 1.7% | $9,685,395 | |
| STATE STREET CORP | 1.2% | 686,772 | +420% | 0% | $8,955,507 |
| AMERIPRISE FINANCIAL INC | 1.2% | 657,971 | 0% | $8,579,978 | |
| Parkman Healthcare Partners LLC | 0.99% | 563,484 | 0.75% | $7,347,831 | |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.91% | 521,082 | +162% | 4.3% | $6,794,909 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.85% | 483,747 | +15% | 0.9% | $6,308,061 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 56,329,219 | $734,345,136 | +$352,395,622 | $13.04 | 108 |
| 2026 Q1 | 32,289,057 | $221,168,507 | +$28,129,270 | $6.85 | 78 |
| 2025 Q4 | 28,744,224 | $114,993,449 | -$59,773,343 | $4.00 | 64 |
| 2025 Q3 | 44,576,107 | $89,598,934 | -$10,311,694 | $2.01 | 66 |
| 2025 Q2 | 49,893,947 | $61,871,600 | -$2,503,034 | $1.24 | 68 |
| 2025 Q1 | 51,939,064 | $63,368,269 | -$8,741,696 | $1.22 | 76 |
| 2024 Q4 | 55,706,408 | $100,272,719 | -$19,354,214 | $1.80 | 78 |
| 2024 Q3 | 54,655,767 | $278,130,509 | +$14,600,273 | $5.09 | 69 |
| 2024 Q2 | 49,901,732 | $354,801,793 | +$245,093,722 | $7.11 | 46 |
| 2024 Q1 | 16,855,387 | $46,194,788 | +$5,051 | $2.74 | 20 |
| 2023 Q4 | 16,853,724 | $45,505,627 | +$348,407 | $2.70 | 22 |
| 2023 Q3 | 16,728,590 | $43,997,383 | -$6,828 | $2.63 | 22 |
| 2023 Q2 | 16,730,361 | $46,844,345 | +$79,298 | $2.80 | 21 |
| 2023 Q1 | 16,702,070 | $48,434,001 | +$194,589 | $2.90 | 19 |
| 2022 Q4 | 16,628,134 | $61,000,699 | +$90,854 | $3.67 | 20 |
| 2022 Q3 | 14,807,225 | $47,821,510 | -$982,037 | $3.23 | 20 |
| 2022 Q2 | 15,127,218 | $45,689,000 | -$21,553,504 | $3.02 | 22 |
| 2022 Q1 | 17,488,772 | $146,733,000 | +$663,723 | $8.39 | 40 |
| 2021 Q4 | 17,373,074 | $181,720,000 | +$142,325 | $10.46 | 34 |
| 2021 Q3 | 17,279,112 | $310,677,000 | +$310,677,000 | $17.98 | 31 |